FY2025 EPS Estimates for Bruker Decreased by Leerink Partnrs

Bruker Corporation (NASDAQ:BRKR) – Stock analysts at Leerink Partnrs dropped their FY2025 earnings per share estimates for shares of Bruker in a research report issued to clients and investors on Thursday, July 17th. Leerink Partnrs analyst P. Souda now anticipates that the medical research company will earn $2.42 per share for the year, down from their prior estimate of $2.46. The consensus estimate for Bruker’s current full-year earnings is $2.69 per share. Leerink Partnrs also issued estimates for Bruker’s Q1 2026 earnings at $0.52 EPS, Q2 2026 earnings at $0.50 EPS, FY2026 earnings at $2.70 EPS and FY2027 earnings at $3.03 EPS.

Bruker (NASDAQ:BRKR) last posted its earnings results on Wednesday, May 7th. The medical research company reported $0.47 EPS for the quarter, beating analysts’ consensus estimates of $0.46 by $0.01. The firm had revenue of $801.40 million during the quarter, compared to the consensus estimate of $763.83 million. Bruker had a return on equity of 19.47% and a net margin of 2.31%. The company’s quarterly revenue was up 11.0% compared to the same quarter last year. During the same period in the prior year, the company earned $0.53 EPS.

Several other analysts have also weighed in on the company. The Goldman Sachs Group decreased their price target on Bruker from $50.00 to $45.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. UBS Group decreased their price target on Bruker from $57.00 to $45.00 and set a “neutral” rating on the stock in a report on Thursday, May 8th. Stifel Nicolaus decreased their price target on Bruker from $57.00 to $48.00 and set a “hold” rating on the stock in a report on Thursday, May 8th. Bank of America decreased their price target on Bruker from $61.00 to $50.00 and set a “buy” rating on the stock in a report on Thursday, June 26th. Finally, Wells Fargo & Company decreased their price target on Bruker from $75.00 to $60.00 and set an “overweight” rating on the stock in a report on Thursday, April 17th. Six investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company’s stock. Based on data from MarketBeat.com, Bruker presently has an average rating of “Hold” and a consensus price target of $52.89.

Bruker Stock Performance

NASDAQ:BRKR opened at $40.55 on Friday. The stock’s fifty day moving average is $39.43 and its 200 day moving average is $44.98. Bruker has a fifty-two week low of $34.10 and a fifty-two week high of $72.94. The firm has a market capitalization of $6.14 billion, a PE ratio of 77.98, a PEG ratio of 2.84 and a beta of 1.18. The company has a debt-to-equity ratio of 1.13, a quick ratio of 0.74 and a current ratio of 1.57.

Hedge Funds Weigh In On Bruker

Several institutional investors have recently made changes to their positions in BRKR. Pinnacle Bancorp Inc. purchased a new position in shares of Bruker during the first quarter valued at $29,000. Allworth Financial LP increased its stake in shares of Bruker by 92.4% during the first quarter. Allworth Financial LP now owns 758 shares of the medical research company’s stock valued at $30,000 after buying an additional 364 shares during the period. Caitong International Asset Management Co. Ltd increased its stake in shares of Bruker by 1,354.5% during the first quarter. Caitong International Asset Management Co. Ltd now owns 800 shares of the medical research company’s stock valued at $33,000 after buying an additional 745 shares during the period. Parallel Advisors LLC increased its stake in shares of Bruker by 63.0% during the second quarter. Parallel Advisors LLC now owns 898 shares of the medical research company’s stock valued at $37,000 after buying an additional 347 shares during the period. Finally, Annis Gardner Whiting Capital Advisors LLC purchased a new position in shares of Bruker during the first quarter valued at $42,000. Hedge funds and other institutional investors own 79.52% of the company’s stock.

Insiders Place Their Bets

In other Bruker news, CEO Frank H. Laukien bought 2,608 shares of Bruker stock in a transaction on Friday, June 6th. The shares were acquired at an average price of $38.36 per share, for a total transaction of $100,042.88. Following the completion of the purchase, the chief executive officer directly owned 38,462,171 shares in the company, valued at approximately $1,475,408,879.56. This trade represents a 0.01% increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 27.30% of the stock is currently owned by insiders.

Bruker Announces Dividend

The firm also recently announced a quarterly dividend, which was paid on Friday, June 27th. Shareholders of record on Monday, June 16th were paid a $0.05 dividend. The ex-dividend date of this dividend was Monday, June 16th. This represents a $0.20 dividend on an annualized basis and a yield of 0.49%. Bruker’s payout ratio is 38.46%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.